Ajanta Pharma’s Growth Story Gets A Semaglutide Boost

Ajanta Pharma Ltd has taken a decisive step in its growth journey by partnering with Biocon to commercialize semaglutide, a GLP-1 receptor agonist widely used in diabetes and obesity treatment. The agreement grants Ajanta exclusive marketing rights in 23 countries and semi-exclusive rights in three others across Africa, the Middle East, and Central Asia.  

Key highlights from the announcement include  

• Ajanta Pharma will market semaglutide in 26 countries, leveraging its established branded generics distribution network.  
• Biocon will act as the manufacturing and supply partner, ensuring product quality and scalability.  
• The patent for semaglutide, currently marketed globally under brands like Wegovy and Ozempic, is set to expire in March 2026 in most of these regions.  
• Ajanta plans to launch its version post-regulatory approvals, expected in late 2026 or early 2027.  
• Analysts project strong financial gains, with EBITDA and PAT growth estimated at 17% and 14% CAGR respectively between FY25–FY28.  
• The company’s return on equity and capital employed are forecasted to reach 28.1% and 35.5% by FY27.  
• Shares of Ajanta Pharma surged nearly 5% in December 2025, hitting a five-month high following the announcement.  
• The move strengthens Ajanta’s presence in emerging markets, aligning with its strategy of expanding in semi-regulated geographies.  
• Industry experts highlight rising global demand for GLP-1 therapies, making semaglutide a lucrative addition to Ajanta’s portfolio.  

This partnership marks a significant milestone for Ajanta Pharma, combining Biocon’s manufacturing expertise with Ajanta’s commercial reach. With semaglutide poised to become a blockbuster generic in the coming years, Ajanta is well-positioned to capture market share and reinforce its growth story in the global pharmaceutical landscape.  

Sources: Business Standard, The Hindu Business Line, India Infoline, Moneycontrol, Businessworld